JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fryer, J. D.
Right arrow Articles by Lukas, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryer, J. D.
Right arrow Articles by Lukas, R. J.

Vol. 288, Issue 1, 88-92, January 1999

Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine

John D. Fryer and Ronald J. Lukas

Division of Neurobiology, Barrow Neurological Institute, Phoenix, Arizona

Nicotinic acetylcholine receptors (nAChR) are diverse members of the neurotransmitter-gated ion channel superfamily and play critical roles in chemical signaling throughout the nervous system. The present study establishes the acute functional effects of bupropion, phencyclidine, and ibogaine on two human nAChR subtypes. Function of muscle-type nAChR (alpha 1beta gamma delta ) in TE671/RD cells or of ganglionic nAChR (alpha 3beta 4alpha 5±beta 2) in SH-SY5Y neuroblastoma cells was measured with 86Rb+ efflux assays. Functional blockade of human muscle-type and ganglionic nAChR is produced by each of the drugs in the low to intermediate micromolar range. Functional blockade is insurmountable by increasing agonist concentrations in TE671/RD and SH-SY5Y cells for each of these drugs, suggesting noncompetitive inhibition of nAChR function. Based on these findings, we hypothesize that nAChR are targets of diverse substances of abuse and agents used in antiaddiction/smoking cessation strategies. We also hypothesize that nAChR play heretofore underappreciated roles in depression and as targets for clinically useful antidepressants.

0022-3565/99/2881-0088$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
M. De Biasi and R. Salas
Influence of Neuronal Nicotinic Receptors over Nicotine Addiction and Withdrawal
Experimental Biology and Medicine, August 1, 2008; 233(8): 917 - 929.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Alkondon and E. X. Albuquerque
Nicotinic Receptor Subtypes in Rat Hippocampal Slices Are Differentially Sensitive to Desensitization and Early in Vivo Functional Up-Regulation by Nicotine and to Block by Bupropion
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 740 - 750.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
K. A. Sacco, K. L. Bannon, and T. P. George
Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders
J Psychopharmacol, December 1, 2004; 18(4): 457 - 474.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. E. Myles, A. M. Azcuy, N. T. Nguyen, E. R. Reisch, S. A. Barker, H. W. Thompson, and J. M. Hill
Bupropion (Zyban, Wellbutrin) Inhibits Nicotine-Induced Viral Reactivation in Herpes Simplex Virus Type 1 Latent Rabbits
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 640 - 644.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol, September 1, 2004; 18(3): 293 - 335.
[PDF]

Home page
 Mol. Pharmacol.Home page
M. I. Damaj, F. I. Carroll, J. B. Eaton, H. A. Navarro, B. E. Blough, S. Mirza, R. J. Lukas, and B. R. Martin
Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors
Mol. Pharmacol., September 1, 2004; 66(3): 675 - 682.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cohen, O. E. Bergis, F. Galli, A. W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, et al.
SSR591813, a Novel Selective and Partial {alpha}4{beta}2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 407 - 420.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. S. Rauhut, S. N. Mullins, L. P. Dwoskin, and M. T. Bardo
Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 664 - 672.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Miller, S. P. Sumithran, and L. P. Dwoskin
Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1113 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. K. Miller, E. H. F. Wong, M. D. Chesnut, and L. P. Dwoskin
Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Bupropion to aid smoking cessation
DTB, October 1, 2000; 38(10): 73 - 75.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. E. Slemmer, B. R. Martin, and M. I. Damaj
Bupropion Is a Nicotinic Antagonist
J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 321 - 327.
[Abstract] [Full Text]

Home page
 JAMAHome page
E. A. Deagle III, T. R. Berigan, D. O. Antonuccio, W. G. Danton, E. F. Domino, J. Goldman, R. D. Shytle, P. R. Sanberg, J. Hughes, M. Goldstein, et al.
Adding Behavioral Therapy to Medication for Smoking Cessation
JAMA, June 2, 1999; 281(21): 1983 - 1985.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.